oral semaglutide news Lowers HbA1c in Phase 3 Trial in Youth With Type 2 Diabetes Dr Reddy's Laboratories launches semaglutide

To view or add a comment, sign in Eli Lilly and Company Reports Additional Positive Phase 3 Results for Retatrutide Across Multiple Obesity-Related Conditions On June 6, Eli Lilly and Company announced additional positive pivotal Phase 3 results for its investigational GLP-1/GIP/GCG triple receptor agonist, #Retatrutide

Retatrutide has a half-life of approximately 6 days, meaning it takes 4 to 5 weeks to reach steady state at any given dose

These on-the-go boosters are effective for revitalizing your bodys vital functions GLP-1 WEIGHT LOSS GLP-1s are medications distinct from previous prescription weight loss drugs such as phentermine, as it targets essential metabolic pathways that promote persistent weight loss

This isn't a replacement for prescribed medical treatment for any health condition